{"analyses":[{"groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"binomial exact test against H0"},{"groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"binomial exact test against H0"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.6","upperLimit":"58.5","value":"45.9"},{"groupId":"OG001","lowerLimit":"34.8","upperLimit":"57.0","value":"45.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"description":"To evaluate anti-tumor activity of Sunvozertinib in advanced NSCLC patients with EGFR Exon20 insertion at defined dose(s) by assessment of Objective Response Rate (ORR).","dispersionType":"97.5% Confidence Interval","groups":[{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized to receive sunvozertinib 200 mg once daily continuously.","id":"OG000","title":"Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized ratio to receive sunvozertinib 300 mg once daily continuously.","id":"OG001","title":"Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"through the study completion, an average of around 1 year for part B","title":"Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).","type":"PRIMARY","unitOfMeasure":"percentage of participants"}